Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Eversana, officially known as Eversana Life Science Services, is a leading provider of commercial services for the life sciences industry, headquartered in the United States. Founded in 2018, the company has rapidly established itself as a key player in the healthcare sector, offering a comprehensive suite of solutions that span market access, patient support, and commercialisation strategies.
With a strong presence across North America and Europe, Eversana is dedicated to enhancing patient outcomes through innovative services tailored to the unique needs of biopharmaceutical companies. Their core offerings, including integrated market access and patient engagement solutions, set them apart by ensuring that therapies reach the patients who need them most. Eversana's commitment to excellence has earned it a notable position in the market, recognised for its ability to drive efficiency and improve patient experiences in an increasingly complex healthcare landscape.
-11 vs industry average
Eversana’s score of 18 is lower than 46% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medical Device Manufacturing has below-average carbon intensity
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
No reported emissions data is available for Eversana yet.
Eversana Life Science Services, LLC, headquartered in the United States, has set ambitious climate commitments despite not having specific carbon emissions data available for the most recent year. The company has committed to significant reductions in greenhouse gas emissions across various scopes.
Eversana aims to reduce its absolute Scope 1 and Scope 2 emissions by 63% by 2035, using 2024 as the base year. Additionally, the company has set a target to reduce its absolute Scope 3 emissions by 37.5% within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C.
As of now, Eversana has not reported any specific emissions totals, but their commitment to substantial reductions reflects a proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emission data, company specific factors and auditable source documents
2035
63% reduction in Scope 2
EVERSANA Life Science Services, LLC commits to reduce absolute scope 2 GHG emissions 63.0% by 2035 from a 2024 base year.
2035
63% reduction in Scope 1
EVERSANA Life Science Services, LLC commits to reduce absolute scope 1 GHG emissions 63.0% by 2035 from a 2024 base year.
2035
37.5% reduction in scope 3 total
EVERSANA Life Science Services, LLC also commits to reduce absolute scope 3 GHG emissions 37.5% within the same timeframe.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more